Is AbbVie Inc. (ABBV) a good stock to buy?

Olyth's institutional analysis of ABBV reveals an Altman Z-Score of 2.00 and a Piotroski F-Score of 8/9. These metrics, combined with its 5-year revenue trend ($61.16B most recent), help investors decide if ABBV fits their risk profile.

What is the current P/E ratio for ABBV?

As of the latest trading session, AbbVie Inc. (ABBV) has a trailing P/E ratio of 87.06.

Who is the CEO of AbbVie Inc.?

The current Chief Executive Officer of AbbVie Inc. is Scott T. Reents.

What was ABBV's revenue for the last 5 years?

According to its latest income statements, AbbVie Inc. reported annual revenues of $61.16B (2025), $56.33B (2024), $54.32B (2023), $58.05B (2022), $56.20B (2021) respectively.

Does ABBV pay a dividend?

AbbVie Inc. currently pays a dividend to its shareholders, with a trailing dividend yield of 3.22%.

How much debt and cash flow does ABBV have?

In its latest reporting period, AbbVie Inc. generated $17.82B in Free Cash Flow against a total debt load of $69.07B.

What is the Price-to-Book (P/B) ratio of AbbVie Inc.?

The Price-to-Book (P/B) ratio for AbbVie Inc. (ABBV) is currently -112.51.

What is the Price-to-Sales (P/S) ratio of ABBV?

Based on trailing twelve-month data, AbbVie Inc. (ABBV) trades at a Price-to-Sales (P/S) ratio of 5.97.

What is AbbVie Inc.'s Return on Equity (ROE)?

AbbVie Inc. (ABBV) has a Return on Equity (ROE) of -361.58%, representing its profitability relative to shareholder equity.

ABBV

AbbVie Inc. · Healthcare

206.65

1.05%(-2.19)

Prev. Close

208.60

0.94%(+1.95)

Pre-market

Last Updated: — ET

52W L: $164.3952W H: $244.81

$207.00

CHG-22.44 (-9.78%)

H$231.26

L$201.80

VOL84M

ABBV (1h)

Company Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

55,000

IPO Date

2013-01-02

Beta

0.36

Websitewww.abbvie.com↗

ABBV

AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note

AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation

High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

Here's Why AbbVie (ABBV) is a Strong Value Stock

How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?

Leo Wealth LLC Raises Holdings in AbbVie Inc. $ABBV